Literature DB >> 22484072

Gamma knife radiosurgery for resectable brain metastasis.

Zhiyuan Xu1, Mohamed Elsharkawy, David Schlesinger, Jason Sheehan.   

Abstract

BACKGROUND: Surgical resection is most often performed for superficially located brain metastasis. We evaluate the use of gamma knife radiosurgery (GKS) for resectable non-small cell lung cancer (NSCLC) brain metastases located <3 cm away from the outer cortical surface.
METHODS: Between 1999 and 2009, 306 patients were treated for brain metastasis from NSCLC at the University of Virginia. The current study included patients with 3 or fewer resectable brain metastases, with resectable being defined as <3 cm from the nearest outer cortical surface of the brain. Sixty-four patients with 111 metastatic brain lesions were eligible for the study. Survival, tumor control, and need for a craniotomy and tumor resection after GKS were evaluated.
RESULTS: The mean overall survival rate in this cohort is 13.5 months (median, 8 months) after GKS, and the mean overall survival after diagnosis of the primary lesion was 31.5 months (median, 19 months). Factors related to prolonged survival after GKS were gender, Karnofsky performance score (KPS), recursive partitioning analysis (RPA) class, age at GKS, number of metastatic lesions, development of new intracranial lesions, and number of lobes involved with metastatic disease. The actuarial local tumor control rate was 84% at 6 months. Two patients (3%) underwent a craniotomy and tumor resection for their progressive superficial metastasis after GKS.
CONCLUSIONS: GKS for NSCLC brain metastases is effective in patients with 3 or fewer resectable tumors. The need for a craniotomy in this subgroup of patients after GKS is very low.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brain metastasis; GKS; Gamma knife radiosurgery; KPS; Karnofsky performance score; MR; Magnetic resonance; NSCLC; Non–small cell lung cancer; RPA; Recursive partitioning analysis; Resectable; SRS; Stereotactic radiosurgery; WBRT; Whole brain radiation therapy

Mesh:

Year:  2012        PMID: 22484072     DOI: 10.1016/j.wneu.2012.03.021

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

Review 1.  Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.

Authors:  Manmeet S Ahluwalia; Kevin Becker; Benjamin P Levy
Journal:  Oncologist       Date:  2018-04-12

2.  Leukoencephalopathy in long term brain metastases survivors treated with radiosurgery.

Authors:  Or Cohen-Inbar; Patrick Melmer; Cheng-chia Lee; Zhiyuan Xu; David Schlesinger; Jason P Sheehan
Journal:  J Neurooncol       Date:  2016-01       Impact factor: 4.130

3.  Identifying better surgical candidates among recursive partitioning analysis class 2 patients who underwent surgery for intracranial metastases.

Authors:  Kaisorn L Chaichana; Shami Acharya; Mariana Flores; Olindi Wijesekera; Daniele Rigamonti; Jon D Weingart; Alessandro Olivi; Chetan Bettegowda; Gary L Gallia; Henry Brem; Michael Lim; Alfredo Quinones-Hinojosa
Journal:  World Neurosurg       Date:  2013-09-25       Impact factor: 2.104

4.  IL-6 receptor is a possible target against growth of metastasized lung tumor cells in the brain.

Authors:  Mami Noda; Yukiko Yamakawa; Naoya Matsunaga; Satoko Naoe; Taishi Jodoi; Megumi Yamafuji; Nozomi Akimoto; Norihiro Teramoto; Kyota Fujita; Shigehiro Ohdo; Haruo Iguchi
Journal:  Int J Mol Sci       Date:  2012-12-27       Impact factor: 5.923

5.  Surgery for brain metastases.

Authors:  Kurt Andrew Yaeger; M Nathan Nair
Journal:  Surg Neurol Int       Date:  2013-05-02

6.  Pathological Evaluation of Radiation-Induced Vascular Lesions of the Brain: Distinct from De Novo Cavernous Hemangioma.

Authors:  Yoon Jin Cha; Ji Hae Nahm; Ji Eun Ko; Hyun Joo Shin; Jong-Hee Chang; Nam Hoon Cho; Se Hoon Kim
Journal:  Yonsei Med J       Date:  2015-11       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.